NEW YORK (360Dx) – Diagnostics companies have shown a high level of interest in the European Commission's Horizon 2020 program focused on test development, with a focus on cancer, infectious diseases, and circulatory diseases dominating the submitted projects.

Of the 1,194 Horizon 2020 proposals received between 2014 and 2017, most were related to the development of markers and devices for in vitro diagnostics, while a third were focused on personalized medicine.